Should You Buy Centrus Energy While It's Below $270?

With U.S. electricity demand expected to rise ~2.5% CAGR and nuclear already supplying 18% of U.S. power, Centrus Energy is positioned as a strategically important supplier—it provides LEU and enrichment services and is the only NRC‑licensed, non‑Russian producer capable of making HALEU for next‑generation reactors. The company currently relies on some Russian LEU (covered by a DOE waiver through 2026–27) and faces a looming need to replace roughly 25% of enriched uranium imports by 2028; meeting that opportunity requires substantial Piketon plant expansion, DOE funding, private capital and long‑term customer commitments. Shares have been highly volatile (this year’s range $50–$464) and trade at about 48.6x projected FY EPS versus 88x at the peak, reflecting high valuation and execution risk—the article argues the pullback could be a tactical way to gain exposure to a potentially pivotal domestic nuclear‑fuel supplier, but timing and policy/funding execution remain the primary risks.

Analysis

U.S. electricity demand is projected to grow about 2.5% CAGR, five times faster than the prior decade, and nuclear already supplies roughly 18% of U.S. power; this backdrop elevates the strategic importance of domestic nuclear fuel suppliers such as Centrus Energy (LEU). Centrus derives the bulk of revenue from its low-enriched uranium (LEU) segment and also generates material revenue from technical services tied to its high-assay low-enriched uranium (HALEU) contract with the Department of Energy, although HALEU reactors are not expected to be commercially active until the late 2020s or early 2030s. Centrus is the only NRC-licensed, non‑Russian producer capable of making HALEU and the only U.S. company with proven enrichment technology for commercial and national security needs, a position Stifel calls "uniquely positioned." The company currently relies on imported LEU (including a commercial agreement with a Russian entity) but has a DOE waiver allowing imports for 2026–27; a phased ban by 2028 creates an urgent need to replace roughly 25% of enriched uranium currently sourced from Russia and makes Piketon plant expansion, DOE funding, private capital and long-term customer commitments critical to execution. Market pricing reflects both the strategic optionality and execution risk: shares traded between $50 and $464 this year, are down 47% from the 52-week high and trade below $270, and the stock sits at about 48.6x projected EPS (versus ~88x at the peak), leaving valuation high and downside sensitive to delays or funding shortfalls.

Key Decisions for Investors

• Consider building only a small, staged position to capture potential upside from domestic HALEU production while limiting exposure to execution risk and valuation sensitivity
• Monitor three catalysts closely before increasing exposure: DOE funding decisions for Piketon, progress on plant expansion and licensing milestones, and replacement/diversification of Russian LEU supply ahead of the expected 2028 phase‑out
• Use hedges or option structures if holding a material position given the stock's wide intra‑year trading range ($50–$464) and high forward P/E of ~48.6x, which amplify downside on missed milestones
• Avoid using Centrus as a short‑term trade for conservative investors; reallocations should be contingent on concrete customer commitments and visible capital funding to support the transition from reseller to producer